{"entity":{"id":"dean-bajorin","kind":"person","name":"Dean F. Bajorin","aka":[],"tldr":"Led CheckMate 274, which established adjuvant nivolumab after bladder cancer surgery.","summary":"Dean Bajorin was principal investigator of CheckMate 274, the trial showing adjuvant nivolumab improves disease-free survival in muscle-invasive urothelial cancer after radical surgery, the first adjuvant immunotherapy approval in the disease. He developed the Bajorin prognostic model for metastatic urothelial cancer and led decades of chemotherapy trials at MSKCC.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bajorin%20DF%5BAuthor%5D%20urothelial%20nivolumab"}],"tags":["urothelial","adjuvant","immunotherapy"],"related":[],"cancers":["urothelial"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":["pd1"],"drugs":["nivolumab"],"companies":[],"institutions":["mskcc"],"pathways":[],"terms":[],"trials":["checkmate-274"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Attending Physician, Genitourinary Oncology, Memorial Sloan Kettering Cancer Center","institutionId":"mskcc","specialisms":["Urothelial cancer","Adjuvant immunotherapy","Chemotherapy","Prognostic models"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bajorin%20DF%5BAuthor%5D%20urothelial%20nivolumab"}],"papers":[{"title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma (CheckMate 274)","journal":"NEJM","year":2021,"doi":"10.1056/NEJMoa2034442"},{"title":"Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy","journal":"JCO","year":1999,"doi":"10.1200/JCO.1999.17.10.3173"}],"orcid":"0000-0003-4001-7088"},"route":"/people/dean-bajorin/","neighbours":{"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"target":[{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/"}],"drug":[{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"}],"institution":[{"id":"mskcc","kind":"institution","name":"Memorial Sloan Kettering Cancer Center","route":"/institutions/mskcc/"}],"trial":[{"id":"checkmate-274","kind":"trial","name":"CheckMate 274","route":"/trials/checkmate-274/"}]}}